Skip to main content
SpringerLink
Log in
Book cover

Preeclampsia pp 9–26Cite as

Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobas®e 411 Analyser

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1710))

Abstract

Preeclampsia is a relatively common pregnancy-related condition associated with serious maternal and fetal morbidity and mortality. It is now well established that anti-angiogenic sFlt1 is upregulated in preeclampsia and binds PlGF and VEGF, causing an imbalance in angiogenic factors with subsequent endothelial injury and dysfunction. Measurement of placental growth factor (PlGF) and the sFlt1/PlGF ratio have both been validated in other countries for screening and diagnosis of preeclampsia and the differentiation of preeclampsia from other hypertensive disorders of pregnancy. There are several automated, commercially available immunoassays capable of measuring PlGF and the sFlt1/PlGF ratio for preeclampsia diagnosis. Here we outline the methodology for using the Roche Cobas ® e 411 immunoassay platform to determine the sFlt1/PlGF ratio.

This is a preview of subscription content, log in via an institution.

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Ghulmiyyah L, Sibai B (2012) Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 36(1):56–59

    Article  Google Scholar 

  2. Khan KS et al (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367(9516):1066–1074

    Article  Google Scholar 

  3. National Collaborating Centre for W.s. and H (2010) Children’s, National Institute for Health and Clinical Excellence: guidance, in hypertension in pregnancy: the management of hypertensive disorders during pregnancy. RCOG Press Royal College of Obstetricians and Gynaecologists, London

    Google Scholar 

  4. WHO (2011) WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. WHO, Geneva

    Google Scholar 

  5. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy (2013) Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol 122(5):1122–1131

    Article  Google Scholar 

  6. GWHO (2011) WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. In: WHO Guidelines Approved by the Guidelines Review Committee. WHO, Geneva

    Google Scholar 

  7. Dekker G, Sibai B (2001) Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 357(9251):209–215

    Article  CAS  Google Scholar 

  8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683

    Article  CAS  Google Scholar 

  9. Redman CW, Sargent IL (2010) Immunology of pre-eclampsia. Am J Reprod Immunol 63(6):534–543

    Article  CAS  Google Scholar 

  10. Maynard SE et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111(5):649–658

    Article  CAS  Google Scholar 

  11. Stepan H (2009) Angiogenic factors and pre-eclampsia: an early marker is needed. Clin Sci (Lond) 116(3):231–232

    Article  CAS  Google Scholar 

  12. Rana S et al (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125(7):911–919

    Article  CAS  Google Scholar 

  13. Liu Y et al (2015) Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 292:507

    Article  CAS  Google Scholar 

  14. Zeisler H, Hund M, Verlohren S (2016) The sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 374(18):1785–1786

    Article  Google Scholar 

  15. Zeisler H et al (2016) Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 374(1):13–22

    Article  CAS  Google Scholar 

  16. Zeisler H et al (2016) Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia. Obstet Gynecol 128(2):261–269

    Article  CAS  Google Scholar 

  17. Verlohren S et al (2012) The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206(1):58.e1–58.e8

    Article  CAS  Google Scholar 

  18. Verlohren S et al (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202(2):161.e1–161.e11

    Article  Google Scholar 

  19. Engels T et al (2013) Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. Hypertens Pregnancy 32(4):459–473

    Article  CAS  Google Scholar 

  20. Sunderji S et al (2010) Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 202(1):40.e1–40.e7

    Article  Google Scholar 

  21. Andersen LB et al (2015) Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens 9(2):86–96

    Article  CAS  Google Scholar 

  22. Benton SJ et al (2011) Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 205(5):469.e1–469.e8

    Article  Google Scholar 

  23. Lehnen H et al (2013) Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria. Geburtshilfe Frauenheilkd 73(5):440–445

    Article  CAS  Google Scholar 

  24. Anderson UD et al (2015) First trimester prediction of preeclampsia. Curr Hypertens Rep 17(9):584

    Article  Google Scholar 

  25. Cobas e 411 analyzer. Operator’s manual. Version 2.1. Roche Diagnostics GmbH. Internal Data on File. See also www.cobas.com

    Google Scholar 

  26. Bramham K et al (2015) [42-OR]: diagnostic accuracy of placental growth factor in women with chronic kidney disease or hypertension and suspected preeclampsia: a prospective cohort study. Pregnancy Hypertens 5(1):21

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia

    Carin Black

  2. Monash Ultrasound for Women, 252-256 Clayton Road, Clayton, VIC, 3168, Australia

    Fabricio da Silva Costa

  3. Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia

    Fabricio da Silva Costa

Authors
  1. Carin Black
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabricio da Silva Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carin Black .

Editor information

Editors and Affiliations

  1. Monash Medical Centre, Monash University, Clayton, Victoria, Australia

    Padma Murthi

  2. INRS-Institut Armand-Frappier, Laval, Québec, Canada

    Cathy Vaillancourt

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Black, C., da Silva Costa, F. (2018). Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobas®e 411 Analyser. In: Murthi, P., Vaillancourt, C. (eds) Preeclampsia . Methods in Molecular Biology, vol 1710. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7498-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7498-6_2

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7497-9

  • Online ISBN: 978-1-4939-7498-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation